Revel Pharmaceuticals
San Francisco, US · Founded 2019 · Delaware corporation
Revel Pharmaceuticals develops enzyme-based therapeutics designed to recognize and reverse molecular damage that accumulates in the body's structural tissue — collagen, elastin, and extracellular matrix — targeting age-related damage that drives disease. The company screens natural enzyme variants against real substrates to identify and engineer them into treatments.
Founders & leadership
Revel Pharmaceuticals was founded in 2019 by Aaron Cravens.
Reported raises · per SEC filings
Form D private placements$7.1M disclosed across 3 rounds · 2019–2022
▶$5.8MraisedMar 2022 · 3 investors · BiotechnologyRule 506(b)
- Aaron James CravensExecutive Officer, Director
- Patrick BurgermeisterDirector
- Jennifer CochranDirector
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$800KraisedApr 2021 · 2 investors · BiotechnologyRule 506(b)
- Jennifer CochranDirector
- Aaron CravensExecutive Officer
- Offering amount
- $1.6M
- Amount sold
- $800K
- Minimum investment
- $100K
- Proceeds to insiders
- $168K
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$533.3KraisedJan 2020 · 2 investors · BiotechnologyRule 506(b)
- Aaron CravensExecutive Officer
- Offering amount
- $1.6M
- Amount sold
- $533.3K
- Minimum investment
- $100K
- Proceeds to insiders
- $158K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $277.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $272.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Revel Pharmaceuticals do?
- Revel Pharmaceuticals develops enzyme-based therapeutics designed to recognize and reverse molecular damage that accumulates in the body's structural tissue — collagen, elastin, and extracellular matrix — targeting age-related damage that drives disease. The company screens natural enzyme variants against real substrates to identify and engineer them into treatments.
- Who founded Revel Pharmaceuticals?
- Revel Pharmaceuticals was founded by Aaron Cravens in 2019.
- How much funding has Revel Pharmaceuticals raised?
- Revel Pharmaceuticals has disclosed $7.1M raised across 3 rounds.
- Where is Revel Pharmaceuticals headquartered?
- Revel Pharmaceuticals is headquartered in San Francisco, US.